Center for Molecular Cardiology, University of Zurich, Wagistrasse 12, CH-8952 Schlieren, Switzerland.
Department of Internal Medicine, University of Genoa, Genoa, Italy.
Cardiovasc Res. 2022 Jul 27;118(10):2385-2396. doi: 10.1093/cvr/cvab300.
Arterial stiffness is a hallmark of vascular ageing that precedes and strongly predicts the development of cardiovascular diseases. Age-dependent stiffening of large elastic arteries is primarily attributed to increased levels of matrix metalloproteinase-2 (MMP-2). However, the mechanistic link between age-dependent arterial stiffness and MMP-2 remains unclear. Thus, we aimed to investigate the efficacy of MMP-2 knockdown using small-interfering RNA (siRNA) on age-dependent arterial stiffness.
Pulse wave velocity (PWV) was assessed in right carotid artery of wild-type (WT) mice from different age groups. MMP-2 levels in the carotid artery and plasma of young (3 months) and old (20-25 months) WT mice were determined. Carotid PWV as well as vascular and circulating MMP-2 were elevated with increasing age in mice. Old WT mice (18- to 21-month old) were treated for 4 weeks with either MMP-2 or scrambled (Scr) siRNA via tail vein injection. Carotid PWV was assessed at baseline, 2 and 4 weeks after start of the treatment. MMP-2 knockdown reduced vascular MMP-2 levels and attenuated age-dependent carotid stiffness. siMMP-2-treated mice showed increased elastin-to-collagen ratio, lower plasma desmosine (DES), enhanced phosphorylation of endothelial nitric oxide synthase (eNOS), and higher levels of vascular cyclic guanosine monophosphate (cGMP). An age-dependent increase in direct protein-protein interaction between MMP-2 and eNOS was also observed. Lastly, DES, an elastin breakdown product, was measured in a patient cohort (n = 64, 23-86 years old), where carotid-femoral PWV was also assessed; here, plasma levels of DES directly correlated with age and arterial stiffness.
MMP-2 knockdown attenuates age-dependent carotid stiffness by blunting elastin degradation and augmenting eNOS bioavailability. Given the increasing clinical use of siRNA technology, MMP2 knockdown should be investigated further as a possible strategy to mitigate age-dependent arterial stiffness and related CV diseases.
动脉僵硬度是血管老化的标志,它先于心血管疾病的发生,并强烈预测其发展。大弹性动脉的年龄依赖性僵硬主要归因于基质金属蛋白酶-2(MMP-2)水平的升高。然而,年龄依赖性动脉僵硬与 MMP-2 之间的机制联系尚不清楚。因此,我们旨在研究使用小干扰 RNA(siRNA)对 MMP-2 敲低对年龄依赖性动脉僵硬的疗效。
在来自不同年龄组的野生型(WT)小鼠的右颈动脉中评估脉搏波速度(PWV)。测定年轻(3 个月)和老年(20-25 个月)WT 小鼠颈动脉和血浆中的 MMP-2 水平。随着年龄的增长,小鼠的颈动脉 PWV 以及血管和循环 MMP-2 均升高。18-21 个月大的老年 WT 小鼠通过尾静脉注射接受 MMP-2 或对照(Scr)siRNA 治疗 4 周。在治疗开始后的基线、2 周和 4 周评估颈动脉 PWV。MMP-2 敲低降低了血管 MMP-2 水平,并减轻了年龄依赖性颈动脉僵硬。siMMP-2 治疗的小鼠表现出弹性蛋白与胶原蛋白比值增加、血浆去甲赖氨酸(DES)降低、内皮型一氧化氮合酶(eNOS)磷酸化增强和血管环鸟苷酸单磷酸(cGMP)水平升高。还观察到 MMP-2 和 eNOS 之间直接的蛋白质-蛋白质相互作用随年龄的增加而增加。最后,在一个包含 64 名患者的队列(年龄 23-86 岁)中测量了 DES(一种弹性蛋白降解产物),并评估了颈动脉-股动脉 PWV;在这里,DES 的血浆水平与年龄和动脉僵硬直接相关。
MMP-2 敲低通过削弱弹性蛋白降解和增加 eNOS 生物利用度来减轻年龄依赖性颈动脉僵硬。鉴于 siRNA 技术的临床应用日益增加,进一步研究 MMP2 敲低作为减轻年龄依赖性动脉僵硬和相关 CV 疾病的一种可能策略是值得的。